Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

被引：27

作者：

Choughule, A. ^{[1
]}

Sharma, R. ^{[1
,2
]}

Trivedi, V. ^{[1
,2
]}

Thavamani, A. ^{[1
,2
]}

Noronha, V. ^{[1
]}

Joshi, A. ^{[1
]}

Desai, S. ^{[3
]}

Chandrani, P. ^{[2
]}

Sundaram, P. ^{[2
]}

Utture, S. ^{[1
]}

Jambhekar, N. ^{[3
]}

Gupta, S. ^{[1
]}

Aich, J. ^{[2
]}

Prabhash, K. ^{[1
]}

Dutt, A. ^{[2
]}

机构：

[1] Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India

[2] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India

[3] Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India

来源：

BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 11期

基金：

英国惠康基金;

关键词：

GROWTH-FACTOR-RECEPTOR; GEFITINIB; THERAPY; GENE; ERLOTINIB; SURVIVAL; FEATURES;

D O I：

10.1038/bjc.2014.401

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2203 / 2204

页数：4

共 50 条

[41] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Fukihara, Jun
Watanabe, Naohiro
Taniguchi, Hiroyuki
Kondoh, Yasuhiro
Kimura, Tomoki
Kataoka, Kensuke
Matsuda, Toshiaki
Yokoyama, Toshiki
Hasegawa, Yoshinori
ONCOLOGY, 2014, 86 (02) : 86 - 93
[42] KRAS mutation in the primary or acquired resistance of Chinese NSCLC to EGFR tyrosine kinase inhibitors
Chen, H.
Wu, Y.
Zhang, X.
Chen, Z.
Guo, A.
Cheng, H.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[43] The Effect of Acquired Cisplatin Resistance on Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Cells
Rho, Jin Kyung
Choi, Yun Jung
Choi, You Ri
Kim, Sun Ye
Choi, Su Jin
Choi, Chang-Min
Na, Im Il
Lee, Jae Cheol
ONCOLOGY RESEARCH, 2011, 19 (10-11) : 471 - 478
[44] Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
Park, Siyeon
Park, Seongyeol
Kim, Tae Min
Kim, Soyeon
Koh, Jaemoon
Lim, Joonoh
Yi, Kijong
Yi, Boram
Ju, Young Seok
Kim, Miso
Keam, Bhumsuk
Kim, Jung Sun
Jeon, Yoon Kyung
Kim, Dong-Wan
Kim, Young Tae
Heo, Dae Seog
EUROPEAN JOURNAL OF CANCER, 2024, 208
[45] AC099850.3/NCAPG Axis Predicts Poor Prognosis and is Associated with Resistance to EGFR Tyrosine-Kinase Inhibitors in Lung Adenocarcinoma
Bao, Jiaqi
Wu, Yanlong
Zhang, Kun
Qi, Huijuan
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 6917 - 6930
[46] Correlation of papillary and bronchioloalveolar patterns in lung adenocarcinoma with EGFR mutation and response to tyrosine kinase inhibitors
Beheshti, J.
Mark, E.
Sabo, E.
Janne, P.
Sequist, L.
Jackman, D.
Joshi, V.
Iafrate, A.
Wang, L.
Meyerson, M.
Lindeman, N.
MODERN PATHOLOGY, 2007, 20 : 318A - 318A
[47] Correlation of papillary and bronchioloalveolar patterns in lung adenocarcinoma with EGFR mutation and response to tyrosine kinase inhibitors
Beheshti, J.
Mark, E.
Sabo, E.
Janne, P.
Sequist, L.
Jackman, D.
Joshi, V.
Iafrate, A.
Wang, L.
Meyerson, M.
Lindeman, N.
LABORATORY INVESTIGATION, 2007, 87 : 318A - 318A
[48] Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung.
Hussain, S
Zakowski, MF
Kris, MG
Ladanyi, M
Pao, W
Riely, G
Rizvi, N
Gomez, JE
Miller, V
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
[49] Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors
Chang, Myung Hee
Ahn, Hee Kyung
Lee, Jeeyun
Jung, Chan-Kwon
Choi, Yoon-La
Park, Yeon Hee
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
CANCER, 2011, 117 (01) : 143 - 151
[50] Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
Chen, K.
Yu, X.
Wang, H.
Huang, Z.
Xu, Y.
Gong, L.
Fan, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1736 - S1737

← 1 2 3 4 5 →